The ACI is pleased to announce the publication of the peer-reviewed academic paper entitled “An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom”. Two… Read More »Academic Paper: An Analysis of Over-the-Counter Cannabidiol Products in the United Kingdom
The ACI congratulate Mile High Labs on the submission of their CBD Novel Foods dossier to the European Food Safety Authority (EFSA) and the UK Food Standards Agency (FSA).
The Food Standards Agency (FSA) confirmed last week, in a virtual meeting with the Association for the Cannabinoid Industry (The ACI), that they intend to stick to their deadline of 31 March 2021 for CBD companies to have a validated Novel Foods application.
The ACI today outlined new plans for The ACI Safety Certification programme. Launched exactly one year before the FSA’s new safety regulations come into force, which excludes all CBD food products from sale in the UK without a validated Novel Foods application dossier.
It has been quite a start to 2020 across our sector, with significant regulatory developments in both the medicinal cannabis and the CBD wellness space.
However, right now we all have to adapt to a new world and the unprecedented challenge a global pandemic presents us all.
A new YouGov poll commissioned by The Association for the Cannabinoid Industry demonstrates overwhelming support for recent FSA guidance concerning CBD
ACI Regulatory and Compliance Lead Dr Parveen Bhatarah Responds to Questions Relating to FSA CBD Guidelines
In the aftermath of the FSA’s announcement relating to CBD regulation and precautionary health advice, the ACI’s Regulatory Lead, Dr Parveen Bhatarah, has compiled the… Read More »ACI Regulatory and Compliance Lead Dr Parveen Bhatarah Responds to Questions Relating to FSA CBD Guidelines
The Association for the Cannabinoid Industry (ACI) today welcomes the new regulatory and precautionary advice published by the Food Standards Agency (FSA).
On the 15th January BBC Two aired a segment on their popular science show Trust Me I’m a Doctor which investigated twelve popular CBD products available in the UK over the counter and online.
Article 4 is a specific provision which allows companies to consult with competent authorities (e.g. The UK FSA) to establish if the product they wish to sell on the market is in fact novel.